JUL 23, 2016 9:01 AM PDT

Research on Rare Gaucher Disease Helps Pinpoint Treatment for Parkinson's Disease

WRITTEN BY: Cassidy Reich
You have probably heard of Parkinson’s Disease (PD), the second most common neurodegenerative disorder after Alzheimer’s. And with PD affecting 2% of the population over the age of 60, you might even know someone with this diagnosis. The disease etiology of PD is complex; it can be sporadic, familial, or caused by environmental factors. One of the strongest genetic risk factors for the development of sporadic PD are genetic mutations in the GBA1 gene that encodes an enzyme called glucocerebrosidase. Glucocerebrosidase is an enzyme that hydrolyzes some species of glycolipids. Defective glucocerebrosidase activity results in lysosomal storage of the glycolipids that cannot be hydrolyzed. The build-up of unhydrolyzed substrates in the lysosomal system leads to cellular stress and dysfunction.  Having one defective copy of this gene increases the risk of developing PD. Having two defective copies of GBA1, however, causes a different, much rarer, disease known as Gaucher disease. Some Gaucher patients develop PD, some don’t. This connection between GBA1, Gaucher, and PD invites a lot of questions into PD and Gaucher pathology and hints at the possibility of a therapeutic being beneficial for both diseases.


Researchers at the NIH investigated that exact possibility. By taking skin cells from patients with Gaucher disease with and without PD, they created induced pluripotent stem cells (iPSCs) that they then differentiated into dopaminergic neurons, the kind of neuron that is targeted in PD.

With these iPSC-derived dopaminergic neurons, the researchers first investigated differences between the neurons derived from patients with Gaucher with PD and Gaucher without PD. All of the cells showed decreased glucocerebrosidase activity and storage of glycolipids, indicating that they faithfully recapitulated the features of Gaucher. The neurons from patients that also have PD also had reduced dopamine storage, reduced dopamine transporter uptake, and increased levels of ?-synuclein, all of which are features of PD.

The next part of this study was to use these iPSC-derived neurons to conduct high-throughput screening to identify small molecules that could ameliorate the pathology of Gaucher. Through this screen, they found a small molecule, NCGC607, that acts as a chaperone for the defective glucocerebrosidase and helps to restore its normal enzymatic function. When applied to iPSC-derived neurons from patients with Gaucher and PD, NCGC607 increased glucocerebrosidase activity, decreased glycolipid storage, and also reduced levels of ?-synuclein.


With results like this, NCGC607 could go into development as a therapeutic for the rare Gaucher disease and the much more common PD. This research is a really wonderful example of looking at a genetic link between a rare disease and common disease and using that link to find a treatment that might work for both.

Sources: Fierce Biotech, NIH, and Journal of Neuroscience
About the Author
  • Cassidy is a curious person, and her curiosity has led her to pursue a PhD in Pharmacology at the New York University Sackler Institute of Biomedical Sciences. She likes to talk about science way too much, so now she's going to try writing about it.
You May Also Like
JAN 15, 2020
Health & Medicine
JAN 15, 2020
The "Normal" Body Temperature Has Decreased
Did you know that the standard human body temperature of 98.6 degrees Fahrenheit was established in 1868? A few modern studies have called this figure into...
FEB 06, 2020
Cell & Molecular Biology
FEB 06, 2020
Taking a Closer Look at a Disease-Linked Protein
Misfolded proteins are closely linked to many neurodegenerative disorders. Researchers have learned more about one of those pathogenic proteins....
FEB 14, 2020
Immunology
FEB 14, 2020
Rewired natural killer cells show promising results in leukemia patients
Natural killer (NK) cells are a subset of white blood cells that are key players in the innate immune system, orchestrating host-rejection responses agains...
FEB 12, 2020
Health & Medicine
FEB 12, 2020
Brain Patients are Advancing Research
Neuroscientists may face the challenge of not having enough material or high-quality material to study the condition they’re researching. Luckily&mda...
FEB 14, 2020
Microbiology
FEB 14, 2020
Beneath the Surface, We All Carry the Same Microbes in Our Skin
Our skin is a critical barrier, and it is made up of three layers. It also carries a community of microbes - a skin microbiome....
FEB 16, 2020
Cell & Molecular Biology
FEB 16, 2020
Growing Cells on Scaffolding as an Alternative to Animal Models
Researchers may have just made it easier for investigators to switch to an engineered model and replace their animal colonies with electrospun synthetics....
Loading Comments...